The Pharma Data

OCTOBER 14, 2020

” About Short Bowel Syndrome Short Bowel Syndrome (SBS) results from extensive intestinal resection due to chronic inflammatory bowel disease (IBD), acute events such as trauma, mesenteric infarction, bariatric surgery or congenital abnormalities. View original content to download multimedia: [link]. Follow us on LinkedIn.

Disease 52

Disease Treatment Therapies Production 52

DrugBank

AUGUST 20, 2024

The world of drug discovery is in a state of transformation, with advancements in biotechnology opening doors to new possibilities for targeting previously "undruggable" disease mechanisms. We also explore why some disease-associated targets remain elusive and how recent innovations are changing that narrative.

Therapies 98

Therapies Pharmaceuticals Disease Research 98

Fierce BioTech

MAY 30, 2024

Quantify Cancer With Methylation-Based ctDNA Detection Download this resource to accelerate your oncology clinical trials, optimize patient enrollment, and monitor minimal residual disease and molecular response effectively.

Clinical Trials 52

Clinical Trials DNA Trials Therapies 52

The Pharma Data

NOVEMBER 26, 2020

(NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein expression system, and Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A.,

Disease 52

Disease Treatment Clinical Trials FDA 52

Fierce BioTech

JUNE 14, 2024

How Spatial Omics Is Unleashing the Potential of Regenerative Medicine Spatial omics, the study of molecular profiles within their spatial context, is revolutionizing regenerative medicine by offering insights into tissue organization and disease pathology.

Disease 52

Disease Research 52

The Open Targets Blog

SEPTEMBER 21, 2023

The Platform's new Associations on the Fly view for Parkinson Disease. The user can quickly see which data sources have evidence supporting the association between Parkinson disease and the prioritised targets, and modify the relative importance of each datasource in the overall association scoring.

Disease 67

Disease Drugs 67

The Pharma Data

JANUARY 26, 2021

27, 2021 /PRNewswire/ — BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the European Patent Office (EPO) has issued a decision to grant European patent EP 2 448 968 B1 for novel antibodies that could be developed into a treatment for Alzheimer’s disease. STOCKHOLM , Jan. About BioArctic AB. SOURCE BioArctic.

Disease 40

Disease Pharmaceutical Companies Treatment Licensing 40

Fierce BioTech

OCTOBER 2, 2023

Logistics For Cell & Gene Therapy Trials: Specific Needs Demand Special Skills Download now to learn more about intricate trial logistics, the importance of expertise, navigating regulations, secure data management, and real case studies like viral vector therapy for Spinal Muscular Atrophy. A specialized provider is essential.

Therapies 52

Therapies Trials Regulations Disease 52

Fierce BioTech

MAY 29, 2024

Characterizing these products and developing robust manufacturing processes can help to usher them to market and provide new treatment options for diseases which are currently challenging to treat. png Sat, 06/01/2024 - 09:00 Biotech Biotech Landing Page Url Download Now Byline Sponsored by: Lonza Read this white paper to learn more.

Treatment 52

Treatment Disease Production Marketing 52

Fierce BioTech

MARCH 28, 2024

Download to learn how Medical Affairs redefines healthcare and improves patient outcomes. Download to learn how Medical Affairs redefine healthcare and improve patient outcomes. Rare Disease Therapeutics biosimilars drug manufacturing Resource Type Whitepaper Eversana-250x190.png

Biosimilars 52

Biosimilars Therapies Disease Drugs 52

PPD

OCTOBER 31, 2024

This issue is particularly pronounced for rare diseases and trials requiring diverse patient populations. Download the full report The post Key Trends Drug Developers Need to Know to Succeed appeared first on PPD. Discover more in-depth insights and trends that are driving industry innovation.

Drug Development 52

Drug Development Clinical Trials Trials Drugs 52

Fierce BioTech

APRIL 10, 2024

Get your FREE white paper to understand the challenges in disease diagnosis, the impact of antibody biomarkers, and the nuances of antibody screening for biomarker discovery.

Disease 52

Disease 52

The Pharma Data

DECEMBER 7, 2020

Download Your Copy. We respect your privacy, by clicking “Download Your Copy” you agree to having your details passed onto the sponsor who may promote similar products and services related to your area of interest subject to their privacy policy. . Download Your Copy. Add bookmark.

Production 52

Production Disease 52

The Pharma Data

NOVEMBER 26, 2020

Download Your Copy. We respect your privacy, by clicking “Download Your Copy” you agree to having your details passed onto the sponsor who may promote similar products and services related to your area of interest subject to their privacy policy. Download Your Copy. . Download Your Copy.

Clinical Trials 52

Clinical Trials Marketing Trials Clinical Supply 52

PPD

AUGUST 16, 2023

While there are improvements to be made, the advantages — including expanded data collection opportunities, artificial intelligence (AI)-enabled insights and efficiencies, patient-friendly trial structures for later clinical trial phases and additional disease states, and clinical trial cost reduction — are far outpacing the drawbacks.

Clinical Trials 98

Clinical Trials Trials Clinical Research FDA 98

Fierce BioTech

JULY 25, 2023

How combining datasets from multiple sources can inform and improve commercial strategies Hundreds of rare disease treatments have entered the market over the past decade—thanks largely to a combination of government incentives, strong urging from patient advocacy groups and advances in cell and gene therapies.

Pharma Companies 52

Pharma Companies Government Therapies Disease 52

The Pharma Data

JANUARY 18, 2021

Potential first-in-class disease-modifying biologic in late-stage clinical studies. a clinical-stage biotechnology company focused on developing treatments for immunological and inflammatory diseases, today announced its launch backed by $80 million Series C financing led by Abingworth LLP.

Disease 40

Disease Science Clinical Development Treatment 40

Fierce BioTech

DECEMBER 14, 2023

Getting the Most from AI in MedTech Takes Data Know-How AI is forecast to save hundreds of thousands of lives, and hundreds of billions of dollars, a year by helping individuals make healthy lifestyle decisions and helping physicians detect disease early. Download now.

Disease 52

Disease Research 52

The Pharma Data

JANUARY 5, 2021

Geriatric, pediatric, and patients suffering from gastroesophageal reflux disease are often administered pharmaceuticals mixed with food or liquids due to difficulty swallowing tablets or capsules. DOWNLOAD TO LEARN MORE>>>> Source link.

Pharmaceuticals 52

Pharmaceuticals Disease 52

Fierce BioTech

JUNE 6, 2023

Download here! Harwell molecular biology spherical nucleic acid rare diseases Adaptive Biotechnologies Resource Type Whitepaper harwell logo.png Tue, 06/06/2023 - 09:31 Content Channel Devices Clinical Data Biotech Content Channel Fierce Biotech Homepage Landing Page Url More Info Byline Sponsored by: Harwell

Science 52

Science Therapies Molecular Biology Government 52

The Pharma Data

OCTOBER 20, 2020

About Ionis Pharmaceuticals As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, drug discovery platform called antisense technology that can treat diseases where no other therapeutic approaches have proven effective. View original content to download multimedia: [link].

RNA 52

RNA Pharmaceuticals Disease Treatment 52

The Pharma Data

MAY 5, 2021

Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. View original content to download multimedia: [link]. To learn more about Lilly , please visit us at?

Disease 52

Disease 52

Drug Channels

FEBRUARY 6, 2024

Access USA will unite PAP – Patient Assistance & Access Programs, Hub and Specialty Pharmacy Models East and the Rare Disease Summit three influential access conferences under one roof for one week of collaborative discussions and opportunities to expand your network and establish powerful partnerships. What is Access USA?

Specialty Pharmacies 40

Specialty Pharmacies Pharmacy Pharma Companies Disease 40

The Open Targets Blog

NOVEMBER 30, 2023

The new page can be accessed from the target-disease associations page when searching for targets associated with a disease, and clicking on the target prioritisation factors tab. Target prioritisation view for Crohn's Disease. Clicking on one of the cells will bring up the data informing the assessment.

Pharmacogenetics 57

Pharmacogenetics Small Molecule Disease Drugs 57

The Pharma Data

SEPTEMBER 11, 2020

This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. View original content to download multimedia: [link]. For more information, visit www.amgen.com and follow us on www.twitter.com/amgen. . SOURCE Amgen. Source link.

Disease 52

Disease 52

The Pharma Data

SEPTEMBER 4, 2020

This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. View original content to download multimedia: [link]. For more information, visit www.amgen.com and follow us on www.twitter.com/amgen. . SOURCE Amgen. Source link.

Disease 52

Disease 52

The ChEMBL-og

MARCH 8, 2023

ChEMBL contains information on drugs that have been approved for treatment of a specific disease / diagnosis (an indication) within a region of the world (e.g. CITRULLINE MALATE ( CHEMBL4297667 ) is under clinical investigation for coronary artery disease at Early Phase 1.

Clinical Trials 40

Clinical Trials FDA Approval Trials Treatment 40

The Pharma Data

AUGUST 7, 2020

The ARM report also showcased robust pipelines of therapies targeting indications in cancers, infectious diseases and inherited disorders. For more pivotal trends from regulatory bodies, download MasterControl’s white paper to find out how the FDA is modernizing its plans to change the regulatory landscape to improve public health.

Clinical Trials 52

Clinical Trials Trials Packaging Therapies 52

The ChEMBL-og

MAY 13, 2021

This paper on the 'Identification of the Core Chemical Structure in SureChEMBL Patents' has recently been published by Maria Falaguera and Jordi Mestres, and the resulting data set is available to download from the SureChEMBL FTP site: [link]. As mentioned above, this data set can be downloaded from SureChEMBL. of the total molecules).

Small Molecule 52

Small Molecule Therapies Disease Drugs 52

The Open Targets Blog

OCTOBER 24, 2023

OMass Therapeutics is using a new technology platform to develop treatments for rare immunological and genetic diseases with high unmet patient needs. We primarily work on immune system diseases, integrating data and analyses from OTG on a large scale. For larger queries, users should look at OTG’s data download options. 

Bioinformatics 62

Bioinformatics Packaging Pharmaceutical Companies Pharma Companies 62

The Pharma Data

OCTOBER 20, 2020

CureLab’s partners in the region will test the efficacy of the company’s DNA-based products against cancers and non-cancerous diseases of chronic inflammation. “There are horrible diseases that are dominant in the GCC region and rarely seen in the West,” said Jihad Fakhreddine. BOSTON , Oct. Source link.

DNA 52

DNA Hospitals International Trials 52

The Pharma Data

NOVEMBER 25, 2020

CAN10 has been designed to block the signalling of the inflammatory cytokines IL-1, IL-33 and IL-36 resulting in unique properties for treatment of inflammatory diseases. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases. Cantargia AB (publ), reg. SOURCE BioInvent.

Clinical Trials 52

Clinical Trials Licensing Licensing International 52

PPD

SEPTEMBER 25, 2023

Historically, clinical trial populations were almost exclusively comprised of white, male participants,  exacerbating gaps in knowledge of diseases and conditions , preventive factors and treatment effectiveness. DOWNLOAD THE FULL REPORT The post New Report Reveals Trends, Opportunities in Drug Development appeared first on PPD Inc.

Drug Development 104

Drug Development Clinical Trials Drugs Trials 104

The Pharma Data

JULY 15, 2021

can now be downloaded for free from App Store and Google Play. We develop solutions and provide services to protect animals from disease and pain. We support our customers in taking care of the health of their animals and protect our communities against life- and society-threatening diseases. The FreVAX app 2.0

Vaccine 52

Vaccine Compliance Disease 52

The Pharma Data

DECEMBER 28, 2020

. “As gynecologists we are trained to look at the inside but many women’s problems originate from the external, not internal, genitalia,” said Dr. Patel, a nationally known expert in vulvar and vaginal diseases, conditions that impact many women but can be challenging to diagnose and treat. SOURCE Northwestern Medicine.

Doctors 52

Doctors Treatment International Disease 52

The Pharma Data

DECEMBER 21, 2020

Our expert and caring medical teams are empowered and supported by industry-leading technology advances and tools for health promotion, disease prevention, state-of-the-art care delivery and world-class chronic disease management. View original content to download multimedia: [link].

Virus 52

Virus Clinical Research Treatment Disease 52

The Pharma Data

DECEMBER 16, 2020

Food and Drug Administration (FDA) has approved Benlysta to treat lupus nephritis (lupus-related kidney disease) in adults. The decision makes Benlysta the first lupus therapy authorized to treat this potentially life-threatening complication of the disease. View original content to download multimedia: [link].

FDA Approval 52

FDA Approval FDA Clinical Trials Treatment 52